IA期子宫内膜癌保留生育功能治疗:系统综述与荟萃分析
该系统综述与荟萃分析纳入754例育龄期IA期子宫内膜样癌患者,比较口服孕激素与左炔诺孕酮宫内缓释系统(LNG-IUD)作为初始孕激素治疗的效果。口服孕激素组12个月内最佳完全缓解率为66%(95%CI 55-76),LNG-IUD组为86%(95%CI 69-95);口服孕激素组妊娠率为58%(95%CI 37-76),LNG-IUD组为44%(95%CI 6-90)。
要点
- 口服孕激素组12个月内完全缓解率为66%(95%CI 55-76),LNG-IUD组为86%(95%CI 69-95)。
- 口服孕激素组妊娠率为58%(95%CI 37-76),LNG-IUD组为44%(95%CI 6-90)。
- 该荟萃分析结果可能有助于为希望保留生育功能的早期子宫内膜癌患者制定个体化治疗决策。
核心结论
- 该荟萃分析为育龄期早期子宫内膜癌患者口服孕激素与LNG-IUD治疗12个月内的有效性提供了有价值的信息。
- 这些发现可能有助于为患者制定个体化治疗决策。
研究设计与样本
- 遵循Cochrane手册指导,对观察性研究和随机对照试验进行系统综述。
- 检索5个数据库和1个试验注册库,时间从建库至2024年4月16日。
- 纳入报告临床IA期子宫内膜样癌育龄期患者接受孕激素治疗后1年内完全缓解的研究。
- 共纳入754例育龄期子宫内膜癌患者,其中490例接受口服孕激素,264例接受LNG-IUD作为初始孕激素治疗。
- 采用比例荟萃分析估计治疗反应,并通过剔除极端效应量研究或剔除2级肿瘤研究进行敏感性分析。
主要发现
- 口服孕激素组12个月内最佳完全缓解的合并比例为66%(95%CI 55-76),LNG-IUD组为86%(95%CI 69-95)。
- 剔除离群研究后,口服孕激素组合并比例为66%(95%CI 57-73),LNG-IUD组为89%(95%CI 75-96),异质性降低。
- 在纳入1级肿瘤的研究中,口服孕激素组合并比例为66%(95%CI 54-77),LNG-IUD组为83%(95%CI 50-96)。
- 口服孕激素治疗后合并妊娠率为58%(95%CI 37-76),LNG-IUD治疗后为44%(95%CI 6-90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The increasing use of fertility-preserving treatments in reproductive-aged patients with early-stage endometrial cancer necessitates robust evidence on the effectiveness of oral progestins and levonorgestrel-releasing intrauterine device. We conducted a systematic review and meta-analysis to examine the outcomes following these 2 primary progestin-based therapies in reproductive-aged patients with early-stage endometrial cancer. DATA SOURCES: We conducted a systematic review of observational studies and randomized controlled trials following the Cochrane Handbook guidance. We conducted a literature search of 5 databases and 1 trial registry from inception of the study to April 16, 2024. STUDY ELIGIBILITY CRITERIA: Studies reporting complete response within 1 year in reproductive-aged patients with clinical stage IA endometrioid cancer undergoing progestin therapy treatment were included. We used data from both observational and randomized controlled studies. STUDY APPRAISAL AND SYNTHESIS METHODS: The primary exposure assessed was the type of progestational treatment (oral progestins or LNG-IUD). The primary outcome was the pooled proportion of the best complete response (CR) within 1 year of primary progestational treatment. We performed a proportional meta-analysis to estimate the treatment response. Sensitivity analyses were performed by removing studies with extreme effect sizes or removing grade 2 tumors. The risk of bias was assessed in each study using the Joanna Briggs Institute critical appraisal checklist. RESULTS: Our analysis involved 754 reproductive-aged patients diagnosed with endometrial cancer, with 490 receiving oral progestin and 264 receiving levonorgestrel-releasing intrauterine device as their primary progestational treatment. The pooled proportion of the best complete response within 12 months of oral progestin and levonorgestrel-releasing intrauterine device treatment were 66% (95% CI, 55-76) and 86% (95% CI, 69-95), respectively. After removing outlier studies, the pooled proportion was 66% (95% CI, 57-73) for the oral progestin group and 89% (95% CI, 75-96) for the levonorgestrel-releasing intrauterine device group, showing reduced heterogeneity. Specifically, among studies including grade 1 tumors, the pooled proportions were 66% (95% CI, 54-77) for the oral progestin group and 83% (95% CI, 50-96) for the levonorgestrel-releasing intrauterine device group. The pooled pregnancy rate was 58% (95% CI, 37-76) after oral progestin treatment and 44% (95% CI, 6-90) after levonorgestrel-releasing intrauterine device treatment. CONCLUSION: This meta-analysis provides valuable insights into the effectiveness of oral progestins and levonorgestrel-releasing intrauterine device treatment within a 12-month timeframe for patients with early-stage endometrial cancer who desire to preserve fertility. These findings have the potential to assist in personalized treatment decision-making for patients.
引用
- Suzuki Y, Ferris JS, Chen L, et al. Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2024. PMID: 39032722. doi:10.1016/j.ajog.2024.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。